复发性脑肿瘤再程放疗:ESTRO中枢神经焦点组综述
该非系统综述由欧洲放射肿瘤学会(ESTRO)中枢神经焦点组撰写,聚焦除外胶质瘤的中枢神经系统肿瘤再程放疗,总结脑膜瘤、室管膜瘤、脑转移瘤、垂体神经内分泌肿瘤及放射性坏死的证据,讨论患者选择、分割方式、技术考虑与安全性,指出多数研究为回顾性且异质性大,需前瞻性研究。
要点
- 再程放疗在严格选择的脑膜瘤、室管膜瘤、脑转移瘤及垂体神经内分泌肿瘤患者中显示潜在疗效与安全性。
- 再程放疗决策需综合既往治疗疗程、分割、危及器官剂量、影像、复发体积及距前次治疗间隔等因素。
- 现有证据多为回顾性、报告缺乏标准化且队列异质性大,亟需设计良好的前瞻性研究。
核心结论
- 不同肿瘤实体的再程放疗研究提示,在仔细选择的患者中可能有效且安全,但证据局限性突出,需前瞻性研究验证。
研究设计与样本
- ESTRO中枢神经焦点组开展的非系统综述,排除胶质瘤,汇总脑膜瘤、室管膜瘤、脑转移瘤、垂体神经内分泌肿瘤再程放疗及放射性坏死管理的相关研究。
主要发现
- 再程放疗在原发性和继发性脑肿瘤中应用的成功程度不一。
- 再程放疗的合理应用需考虑既往治疗疗程、分割方式、危及器官剂量、影像表现、复发肿瘤体积及距前次治疗间隔等多因素。
- 绝大多数现有研究受限于回顾性设计、报告缺乏标准化以及队列与治疗间的整体异质性。
关键数值与推荐
- 再程放疗决策需综合既往治疗疗程、分割、危及器官剂量、影像、复发体积及治疗间隔等因素。
临床怎么用
- 对除外胶质瘤的复发性脑肿瘤,可在仔细选择患者并综合既往治疗、剂量、影像与复发体积等因素后考虑再程放疗。
局限性
- 现有研究多为回顾性设计,报告缺乏标准化,队列与治疗间存在整体异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clin Transl Radiat Oncol . 2026 Aug 10;62:101260. doi: 10.1016/j.ctro.2026.101260. eCollection 2027 Jan. ABSTRACT PURPOSE: Reirradiation has become an area of increasing clinical and scientific interest, particularly in neuro-oncology. This non-systematic review on central nervous system (CNS) tumors by the CNS focus group of the European Society for Radiotherapy and Oncology provides a pragmatic synthesis of the available evidence, excluding gliomas. We address key questions related to patient selection, fractionation, technical considerations, and treatment safety. METHODS: Relevant studies on the use of reirradiation for meningiomas, ependymomas, brain metastases, and pituitary neuroendocrine tumors, as well as on the management of radiation necrosis, have been reviewed and summarized. RESULTS: Reirradiation has been used with varying success in primary and secondary brain tumors. The appropriate use of reirradiation requires consideration of numerous factors, including, but not limited to, prior treatment courses, fractionation, dose to organs at risk, imaging findings, the volume of the recurrent tumor, and the interval since prior treatments. The vast majority of available studies are limited by their retrospective design, lack of standardization in reporting, and overall heterogeneity across cohorts and treatments. CONCLUSION: Several reirradiation studies across different tumor entities suggest potential efficacy and safety in carefully selected patients. However, important limitations remain, underscoring the need for well-designed prospective studies with rigorous reporting in both primary and secondary brain tumors. PMID: 42835612 | PMC: PMC13635515 | DOI: 10.1016/j.ctro.2026.101260
引用
- PubMed 顶刊 · 中枢神经:Reirradiation of recurrent brain tumors: a review by the ESTRO CNS Focus Group
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。